Clinical Trials Market Research Report by Design, Phase, Indication, Country - North America Forecast to 2027 - Cumulative Impact of COVID-19

The North America Clinical Trials Market size was estimated at USD 8,242.53 million in 2021 and expected to reach USD 8,931.56 million in 2022, and is projected to grow at a CAGR 8.88% to reach USD 13,737.47 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Clinical Trials to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Design, the market was studied across Interventional Study and Observational Study. The Interventional Study is further studied across Adaptive Clinical Trial, Non-randomized Control Trial, and Randomized Control Trial. The Observational Study is further studied across Case Control Study, Cohort Study, Cross Sectional Study, and Ecological Study.

Based on Phase, the market was studied across Phase I, Phase II, Phase III, and Phase IV.

Based on Indication, the market was studied across Autoimmune/Inflammation, Cardiovascular, CNS condition, Diabetes, Infectious Diseases, Obesity, Oncology, and Pain management.

Based on Country, the market was studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Clinical Trials market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clinical Trials Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Clinical Trials Market, including Accell Clinical Research, LLC, Atlant Clinical Ltd., Charles River Laboratories International, Inc., Clinipace, Eli Lilly and Company, Icon PLC, IQVIA Holdings, Inc., Novo Nordisk A/S, Parexel International Corporation, Pfizer Inc., ProPharma Group Holdings, LLC, SGS S.A., SIRO Clinpharm Private Limited, Syneos Health, Inc., Thermo Fisher Scientific Inc., and Wuxi AppTec Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the North America Clinical Trials Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Clinical Trials Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Clinical Trials Market?
4. What is the competitive strategic window for opportunities in the North America Clinical Trials Market?
5. What are the technology trends and regulatory frameworks in the North America Clinical Trials Market?
6. What is the market share of the leading vendors in the North America Clinical Trials Market?
7. What modes and strategic moves are considered suitable for entering the North America Clinical Trials Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Clinical Trials Market, by Design
6.1. Introduction
6.2. Interventional Study
6.3.1. Adaptive Clinical Trial
6.3.2. Non-randomized Control Trial
6.3.3. Randomized Control Trial
6.3. Observational Study
6.4.1. Case Control Study
6.4.2. Cohort Study
6.4.3. Cross Sectional Study
6.4.4. Ecological Study

7. Clinical Trials Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV

8. Clinical Trials Market, by Indication
8.1. Introduction
8.2. Autoimmune/Inflammation
8.3. Cardiovascular
8.4. CNS condition
8.5. Diabetes
8.6. Infectious Diseases
8.7. Obesity
8.8. Oncology
8.9. Pain management

9. Canada Clinical Trials Market
9.1. Introduction

10. Mexico Clinical Trials Market
10.1. Introduction

11. United States Clinical Trials Market
11.1. Introduction

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Accell Clinical Research, LLC
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Atlant Clinical Ltd.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Charles River Laboratories International, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Clinipace
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Eli Lilly and Company
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Icon PLC
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. IQVIA Holdings, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Novo Nordisk A/S
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Parexel International Corporation
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Pfizer Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. ProPharma Group Holdings, LLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. SGS S.A.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. SIRO Clinpharm Private Limited
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Syneos Health, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Thermo Fisher Scientific Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Wuxi AppTec Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing